Immunotherapy for cancer patients

Immunotherapy for cancer patients is experiencing a global renaissance. In particular, recently approved substances to activate T cells, so-called Checkpoint inhibitors (PDL-1 / PD-1 and CTL4 antibodies) have currently achieved a breakthrough in oncology in indications, previously considered totally incurable. The authorization for malignant melanoma, kidney- and lung cancer has already been made and approvals for additional indications are expected shortly.

We have found that the combination of these checkpoint inhibitors is especially promising in the combination with local regional and whole body hyperthermia and an immunotherapy, called interleukin 2 (IL-2). The safety and tolerability of this method was published in 2006 by the group of Prof. Redmond and at York University in Ireland [1].

We have successfully submitted the first interim analysis of this promising immunotherapy at the American Cancer Society ASCO and the European Society for cancer EORTC in spring 2016 [2].


[1] O'Brien GC, Cahill RA, Bouchier-Hayes DJ, Redmond HP. Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma. Ir J Med Sci. 2006 Jan-Mar;175(1):10-4.

[2] Kleef R et al. Near complete remission of pulmonary metastasis in triple negative breast cancer (TNBC) using low dose immune check point inhibitors (IC) with interleukin-2 (IL-2) and fever range hyperthermia. Abstract #166013, ASCO Annual meeting; Chicago, June 3-7, 2016 and 3rd Immunotherapy of Cancer Conference; Munich: European Journal of Cancer S1-S30; 2016 p. S29-S30.

Interesting pages for you.

Auhofstraße 1 A-1130 Wien
Tel +43/1/585 73 11
Fax +43/1/585 73 11 - 20